Overview
Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer
Status:
Unknown status
Unknown status
Trial end date:
2018-08-01
2018-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
In this study, the relationship between DPD and the effects of S-1 combined with oxaliplatin chemotherapy were investigated in 200 patients with gastrointestinal carcinoma.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Xijing HospitalTreatments:
Oxaliplatin
Criteria
Inclusion Criteria:- Age ≧18;
- Histologically or cytologically confirmed gastrointestinal cancer;
- ECOG ≦2;
- Physician's intention to treat with S-1 combined with platinum regimen on disease
status and clinical judgment;
- Life expectancy of at least three months;
- Written informed consent to participate in the trial;
Exclusion Criteria:
- History of severe hypersensitivity reactions to the ingredients of S-1 or oxaliplatin;
- Inadequate hematopoietic function which is defined as below:
- white blood cell (WBC) less than 3,500/mm^3
- absolute neutrophil count (ANC) less than 1,500/mm^3
- platelets less than 80,000/mm^3
- Inadequate hepatic or renal function which is defined as below:
- serum bilirubin greater than 1.5 times the upper limit of normal range
- alanine aminotransferase (ALT) or aspartate aminotransferase (AST)
- greater than 2.5 times the ULN if no demonstrable liver metastases or
- greater than 5 times the ULN in the presence of liver metastases
- blood creatinine level greater than 2 times ULN
- Presence of peripheral neuropathy;
- Receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine
drug;
- Women who is pregnant or lactating or fertile women of child-bearing potential unless
using a reliable and appropriate contraceptive method throughout the treatment period
(Including male);
- Psychiatric disorder or symptom that makes participation of the patient difficult;
- Concomitant illness that might be aggregated by active, non-controlled disease such as
congestive heart failure, ischemic heart disease, uncontrolled hypertension or
arrhythmia with in six months;
- Severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed
interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure,
poorly-controlled diabetes;
- Known DPD deficiency;
- Receiving a concomitant treatment with sorivudine or Brivudine within two months;